584 related articles for article (PubMed ID: 31350538)
41. Therapeutic effects of histone deacetylase inhibitors on heart disease.
Chun P
Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
[TBL] [Abstract][Full Text] [Related]
42. The nonepigenetic role for small molecule histone deacetylase inhibitors in the regulation of cardiac function.
Romanick SS; Ferguson BS
Future Med Chem; 2019 Jun; 11(11):1345-1356. PubMed ID: 31161804
[TBL] [Abstract][Full Text] [Related]
43. Deacetylation of nonhistone proteins by HDACs and the implications in cancer.
Peng L; Seto E
Handb Exp Pharmacol; 2011; 206():39-56. PubMed ID: 21879445
[TBL] [Abstract][Full Text] [Related]
44. Chemical and structural biology of protein lysine deacetylases.
Yoshida M; Kudo N; Kosono S; Ito A
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(5):297-321. PubMed ID: 28496053
[TBL] [Abstract][Full Text] [Related]
45. Modulation of cellular processes by histone and non-histone protein acetylation.
Shvedunova M; Akhtar A
Nat Rev Mol Cell Biol; 2022 May; 23(5):329-349. PubMed ID: 35042977
[TBL] [Abstract][Full Text] [Related]
46. The Acyl-CoA Specificity of Human Lysine Acetyltransferase KAT2A.
Anmangandla A; Ren Y; Fu Q; Zhang S; Lin H
Biochemistry; 2022 Sep; 61(17):1874-1882. PubMed ID: 35995428
[TBL] [Abstract][Full Text] [Related]
47. The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis.
Zhao TC; Wang Z; Zhao TY
Atherosclerosis; 2020 Jun; 303():36-42. PubMed ID: 32535412
[TBL] [Abstract][Full Text] [Related]
48. Histone deacetylases in memory and cognition.
Penney J; Tsai LH
Sci Signal; 2014 Dec; 7(355):re12. PubMed ID: 25492968
[TBL] [Abstract][Full Text] [Related]
49. Lysine Acetylation of Proteins and Its Characterization in Human Systems.
Orren DK; Machwe A
Methods Mol Biol; 2019; 1983():107-130. PubMed ID: 31087295
[TBL] [Abstract][Full Text] [Related]
50. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
[TBL] [Abstract][Full Text] [Related]
51. Post-translational modifications talk and crosstalk to class IIa histone deacetylases.
Guttzeit S; Backs J
J Mol Cell Cardiol; 2022 Jan; 162():53-61. PubMed ID: 34416247
[TBL] [Abstract][Full Text] [Related]
52. Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.
López JE; Sullivan ED; Fierke CA
ACS Chem Biol; 2016 Mar; 11(3):706-16. PubMed ID: 26907466
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic potential for HDAC inhibitors in the heart.
McKinsey TA
Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
[TBL] [Abstract][Full Text] [Related]
54. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment.
Colussi C; Illi B; Rosati J; Spallotta F; Farsetti A; Grasselli A; Mai A; Capogrossi MC; Gaetano C
Pharmacol Res; 2010 Jul; 62(1):3-10. PubMed ID: 20227503
[TBL] [Abstract][Full Text] [Related]
55. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
[TBL] [Abstract][Full Text] [Related]
56. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
57. Updating a Strategy for Histone Deacetylases and Its Inhibitors in the Potential Treatment of Cerebral Ischemic Stroke.
Xu Y; Wang Q; Chen J; Ma Y; Liu X
Dis Markers; 2020; 2020():8820803. PubMed ID: 32963637
[TBL] [Abstract][Full Text] [Related]
58. Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.
Wang Z; Zhao YT; Zhao TC
Exp Biol Med (Maywood); 2021 Jan; 246(2):213-225. PubMed ID: 32727215
[TBL] [Abstract][Full Text] [Related]
59. Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.
Ononye SN; van Heyst M; Falcone EM; Anderson AC; Wright DL
Pharm Pat Anal; 2012 May; 1(2):207-21. PubMed ID: 24163736
[TBL] [Abstract][Full Text] [Related]
60. Acetylation of non-histone proteins modulates cellular signalling at multiple levels.
Spange S; Wagner T; Heinzel T; Krämer OH
Int J Biochem Cell Biol; 2009 Jan; 41(1):185-98. PubMed ID: 18804549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
